Advanced Medical Isotope Corporation (OTC:ADMD)
719 Jadwin Avenue. Richland, Washington 99352 US
T: 509.736.4000 E: mkorenko@isotopeworld.com

Tags

Latest News

Click here for more news and updates

Twitter • Industry News


Management & Consultants

Dr. Mike Korenko
Dr. Mike Korenko

Dr. Mike Korenko
President • CEO

 

Dr. Korenko formerly served as Vice-President of Westinghouse, where he was tasked with overseeing 300 and 400 areas, including the Fast Flux Testing Facility (FFTF) and all engineering, safety analysis, and projects for the Hanford site. He also served as Executive Vice President of Closure for Safe Sites of Colorado at Rocky Flats. His most previous assignment was as Chief Operating Officer for Curtiss-Wright, producer of the nuclear components for all the United States submarine and aircraft carriers, as well as components for commercial nuclear power companies.

 

Dr. Korenko has a Doctor of Science from MIT, was a NATO Postdoctoral Fellow at Oxford University, and was selected as a White House Fellow for the Department of Defense, reporting to Secretary Cap Weinberger. Dr. Korenko currently is the author of 28 patents and has received many awards, including the National Energy Resources Organization Research and Development Award, the U.S. Steelworkers Award for Excellence in Promoting Safety, and the Westinghouse Total Quality Award for Performance Manager of the Year.

Leonard Bruce Jolliff
Leonard Bruce Jolliff

Leonard Bruce Jolliff
Chief Financial Officer

 

Leonard Bruce Jolliff, joined Advanced Medical Isotope Corporation as Chief Financial Officer in 2006.  For nine years prior to joining the Company, Mr. Jolliff was a sole practitioner in the role of CFO for Hire and as a Forensic Accountant, working with companies ranging from Fortune 500 to small family operations.  Mr. Jolliff is a CPA and a member of the Washington Society of CPAs.  He is also a Certified Fraud Examiner and a member of the Association of Certified Fraud Examiners.  Mr. Jolliff has held CFO and Controller positions in an array of industries and has worked as a CPA in public practice. Currently all of Mr. Jolliff’s energy is focused on supporting AMI’s isotope production and securing new investments which will enable the growing company to meet it’s goals.

Dr. David J. Swanberg
Dr. David J. Swanberg

Dr. David J. Swanberg

 

Mr. Swanberg has over 30 years’ experience in Radiochemical Processing, Medical Isotope Production, Nuclear Waste Management, Materials Science, Regulatory Affairs, and Project Management.  He has worked in diverse organizations ranging from small start-up businesses to corporations with multi-billion dollar annual revenues.  He previously served as Executive Vice President of Operations for IsoRay Medical Inc. managing day-to-day operations, R&D, and New Product Development.  Mr. Swanberg was a co-founder of IsoRay and led the initial Cs-131 brachytherapy seed product development, FDA 510(k) submission/clearance, and NRC Sealed Source review and registration. He led the radiation dosimetry evaluations to meet American Association of Physicists in Medicine guidelines and is a current member of the AAPM.  

Mr. Swanberg served on the IsoRay Board of Directors and participated in several capital financing rounds totalling over $30M.  He holds a BA in Chemistry from Bethel University (MN) and an MS in Chemical Engineering from Montana State University.  He has numerous technical publications and holds several patents.

Dr. Donald A. Ludwig
Dr. Donald A. Ludwig

Dr. Donald A. Ludwig
 

Donald A. Ludwig, PhD., is Director of Special Projects for AMI. As an expert in particle accelerator applications in radiation therapy, nuclear medicine and radioisotope production Dr. Ludwig also serves as an advisor to numerous entities in the field, both domestic and foreign. Among these are the Atomic Energy of Canada, the U. S. Department of Energy Labs at Los Alamos, Berkeley, Fermi, Hanford and Oak Ridge, the Israel Atomic Energy Agency, the Australian Nuclear Science and Technology Organization, the Budker Institute of Nuclear Physics in Novosibirsk, Siberia, the Malaysian Institute of Nuclear Technology and the Bhabha Atomic Research Center in Mumbai, India. He holds advanced degrees in nuclear physics, medical physics and marketing from top tier Universities.  Dr. Ludwig’s endeavors for AMIC are focused on facilitating the return of clinical radioisotope production to the US, and aiding AMIC in becoming the largest provider of radioisotopes in North America.

Dr. Nigel R. Stevenson
Dr. Nigel R. Stevenson

Dr. Nigel R. Stevenson

Dr. Stevenson is AMIC's Chief Science Officer. He brings with him an impressive background in isotope production. He began his career as a research scientist at TRIUMF, the Canadian Accelerator Facility, before heading up the Isotope Production and Applied Technology group at TRIUMF responsible for the production of a wide variety of radioactive medical isotopes for Nordion in addition to specialized isotope production technology. In 1999 he became the V.P. of Isotope Production and Research for Theragenics Corporation in Atlanta, GA.  In this role he was responsible for installing and operating the world’s largest cyclotron facility (14 machines) used to produce radiochemicals for pharmaceuticals and medical devices. He also had technical oversight of a large scale stable isotope separation facility in Oak Ridge, TN.  He was appointed the Chief Operating Officer of Trace Life Sciences, before assuming his current role as Chief Operating Officer of Clear Vascular.  Additionally, he is the CEO of TcNet, LLC, a company that is investigating the use of PET cyclotron systems to produce a number of additional radiochemicals.  Dr. Stevenson obtained his Ph.D. at the University Of London, UK in 1983 in Nuclear Physics.